JP6920369B2 - ガンマ線照射血清を用いた間葉系幹細胞の培養方法 - Google Patents
ガンマ線照射血清を用いた間葉系幹細胞の培養方法 Download PDFInfo
- Publication number
- JP6920369B2 JP6920369B2 JP2019098293A JP2019098293A JP6920369B2 JP 6920369 B2 JP6920369 B2 JP 6920369B2 JP 2019098293 A JP2019098293 A JP 2019098293A JP 2019098293 A JP2019098293 A JP 2019098293A JP 6920369 B2 JP6920369 B2 JP 6920369B2
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- fbs
- gamma
- stem cells
- sterilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012258 culturing Methods 0.000 title claims description 32
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 18
- 210000002966 serum Anatomy 0.000 title description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 290
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 140
- 239000012091 fetal bovine serum Substances 0.000 claims description 140
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 128
- 229930003268 Vitamin C Natural products 0.000 claims description 128
- 235000019154 vitamin C Nutrition 0.000 claims description 128
- 239000011718 vitamin C Substances 0.000 claims description 128
- 210000000130 stem cell Anatomy 0.000 claims description 91
- 239000002609 medium Substances 0.000 claims description 66
- 230000005251 gamma ray Effects 0.000 claims description 51
- 239000001963 growth medium Substances 0.000 claims description 45
- 210000000577 adipose tissue Anatomy 0.000 claims description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- 230000001678 irradiating effect Effects 0.000 claims description 8
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 claims description 7
- 239000006143 cell culture medium Substances 0.000 claims description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 229960000890 hydrocortisone Drugs 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 231100000987 absorbed dose Toxicity 0.000 claims description 2
- 210000002510 keratinocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 56
- 238000011282 treatment Methods 0.000 description 39
- 239000003963 antioxidant agent Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 18
- 229960005070 ascorbic acid Drugs 0.000 description 17
- 239000013641 positive control Substances 0.000 description 17
- 230000003078 antioxidant effect Effects 0.000 description 16
- 239000011668 ascorbic acid Substances 0.000 description 15
- 230000005855 radiation Effects 0.000 description 15
- 235000010323 ascorbic acid Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 230000006378 damage Effects 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 2
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 2
- 239000011615 dehydroascorbic acid Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000005837 radical ions Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100029529 Thrombospondin-2 Human genes 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000007443 liposuction Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本発明の用語「ビタミンC前処理」または「AA2P前処理」とは、抗酸化剤をFBSに処理し、ガンマ滅菌することを意味する。つまり、抗酸化剤が含まれているFBSを培養培地に追加することである。
本発明の用語「ビタミンCの後処理」または「AA2P後処理」とは、抗酸化剤が含まれていないFBSをガンマ滅菌し、培養培地に処理するとき、抗酸化剤を一緒に培地に追加することを意味する。
細胞治療剤として用いるための幹細胞の培養において、熱不活性化または濾過などでは解決できない感染などの危険要素を除去することができる方法として、無血清培養またはガンマ線滅菌FBSを用いることができる。
脂肪吸引(Liposuction)により腹部脂肪から得られたヒト脂肪組織を分離し、PBSで洗浄した。組織を細切した後、コラゲナーゼタイプ1(collagenase type1)(1mg/ml)を添加したDMEM培地を用いて、37℃で2時間組織を分解させた。コラゲナーゼ処理された組織をPBSで洗浄した後、1000rpmで5分間遠心分離して上清を除去し、ペレットをPBSで洗浄した後、1000rpmで5分間遠心分離した。100μmメッシュで濾過して浮遊物を除去した後、PBSで洗浄し、10%のFBS、2mMのNAC(N−acetyl−Lcysteine)、0.2mMのアスコルビン酸が添加されたDMEM培地で培養した。一晩経過後、付着されていない細胞をPBSで洗浄し、付着された細胞は、5%のFBS、2mMのNAC、0.2mMのアスコルビン酸、0.09mMのカルシウム、5ng/mlのrEGF、5μg/mlのインスリン、10ng/mlのbFGF、および74ng/mlのヒドロコルチゾンを含有するKeratinocyte−SFM培地を2日おきに交換しながら継代培養して、脂肪組織由来の間葉系幹細胞を分離した。
ウシ胎仔血清(FBS;fetal bovine serum)に25kGyのガンマ線を照射((株)SOYAGREENTEC)することで、ガンマ線滅菌されたFBSを準備した。
倍増時間 (Doubling Time)= デュレイション (duration) x log(2)/log(最終濃度)−log(初期濃度)
ウシ胎仔血清(FBS;fetal bovine serum)に25kGyのガンマ線を照射してガンマ線滅菌FBSを準備し、FBSにビタミンC(アスコルビン酸;L−Ascorbic Acid 2−phosphate)を添加した後、25kGyのガンマ線を照射することで、ビタミンCが前処理されたガンマ線滅菌FBSを準備した。ビタミンCは、FBSに対して0.1%または1%の濃度で添加した。
実施例3と同様に、ウシ胎仔血清(FBS;fetal bovine serum)に25kGyのガンマ線を照射してガンマ線滅菌FBSを準備し、FBSにビタミンC(アスコルビン酸;L−Ascorbic Acid 2−phosphate)を添加した後、25kGyのガンマ線を照射することで、ビタミンCが前処理されたガンマ線滅菌FBSを準備した。ビタミンCは、FBSに対して1%の濃度で添加した。
ウシ胎仔血清(FBS;fetal bovine serum)に30kGyのガンマ線を照射してガンマ線滅菌FBSを準備し、FBSにビタミンC(アスコルビン酸;L−Ascorbic Acid 2−phosphate)を添加した後、30kGyのガンマ線を照射することで、ビタミンCが前処理されたガンマ線滅菌FBSを準備した。ビタミンCは、FBSに対して1%の濃度で添加した。
ウシ胎仔血清(FBS;fetal bovine serum)に30kGyのガンマ線を照射してガンマ線滅菌FBSを準備し、前記ガンマ線滅菌FBSが5%で含まれたAMSC+培養培地((株)RBio)に1%ビタミンCが添加された培地(ビタミンC後処理実験群)を準備した。
実施例6の陽性対照群およびビタミンC後処理実験群で、4継代(passage 4)の幹細胞の純度および特性を調査した。
Claims (6)
- (a)ウシ胎仔血清(FBS;fetal bovine serum)にガンマ線を照射するステップと、
(b)前記ガンマ線照射ウシ胎仔血清にビタミンC(ascorbic acid)を
添加した後、幹細胞培養培地であるKSFM−P培地とDMEM培地の混合培地に添加するステップと、
(c)前記培養培地を用いて間葉系幹細胞を培養するステップと、を含む、間葉系幹細胞の培養方法。 - 前記ビタミンCは、前記前記ガンマ線照射ウシ胎仔血清に対して0.025%〜1%の濃度で添加されることを特徴とする請求項1に記載の間葉系幹細胞の培養方法。
- 前記ステップ(b)のウシ胎仔血清は、2〜10%の濃度で添加されることを特徴とする請求項1又は2に記載の間葉系幹細胞の培養方法。
- 前記KSFM−P培地 は、 L-アスコルビン酸2-リン酸 、インスリン、N−アセチル
−L−システイン、塩化カルシウム、ヒドロコルチゾンおよびFBSを含むDefinedケラチノサイト−SFMであることを特徴とする請求項1〜3のいずれか一項に記載の間葉系幹細胞の培養方法。 - 前記ガンマ線照射は、吸収線量が20〜35kGyであることを特徴とする請求項1〜4のいずれか一項に記載の間葉系幹細胞の培養方法。
- 前記間葉系幹細胞は、脂肪組織由来であることを特徴とする請求項1〜5のいずれか一項に記載の間葉系幹細胞の培養方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180059594 | 2018-05-25 | ||
KR10-2018-0059594 | 2018-05-25 | ||
KR10-2019-0060757 | 2019-05-23 | ||
KR1020190060757A KR102172970B1 (ko) | 2018-05-25 | 2019-05-23 | 감마선 조사 혈청을 이용한 중간엽 줄기세포의 배양방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019201640A JP2019201640A (ja) | 2019-11-28 |
JP6920369B2 true JP6920369B2 (ja) | 2021-08-18 |
Family
ID=68615216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019098293A Active JP6920369B2 (ja) | 2018-05-25 | 2019-05-27 | ガンマ線照射血清を用いた間葉系幹細胞の培養方法 |
Country Status (2)
Country | Link |
---|---|
US (1) | US11932874B2 (ja) |
JP (1) | JP6920369B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6826744B1 (ja) * | 2020-07-17 | 2021-02-10 | 医療法人Yanaga CLinic | 成熟脂肪細胞含有組成物の製造方法 |
CN113215095B (zh) * | 2021-05-26 | 2023-03-31 | 生物岛实验室 | 组合物、培养基补充剂以及干细胞培养基及培养方法 |
CN115433712B (zh) * | 2022-10-25 | 2023-05-26 | 任殿明 | 一种脐带间充质干细胞增殖培养基及培养方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0404656D0 (en) | 2004-03-02 | 2004-04-07 | Univ Manchester | Treatment of spinal conditions |
US10179900B2 (en) | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
US20130134849A1 (en) * | 2011-11-28 | 2013-05-30 | Peter F. Menzel | Instrument storage cabinet system |
KR101523040B1 (ko) | 2012-06-26 | 2015-05-26 | 라정찬 | 고농도의 줄기세포 제조방법 |
EP3252146B1 (en) | 2014-10-29 | 2021-09-15 | R Bio Co., Ltd | Medium composition for culturing stem cells |
KR20160050412A (ko) | 2014-10-29 | 2016-05-11 | 주식회사 알바이오 | 줄기세포 배양을 위한 배지조성물 |
-
2019
- 2019-05-24 US US16/422,525 patent/US11932874B2/en active Active
- 2019-05-27 JP JP2019098293A patent/JP6920369B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20190359942A1 (en) | 2019-11-28 |
US11932874B2 (en) | 2024-03-19 |
JP2019201640A (ja) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6920369B2 (ja) | ガンマ線照射血清を用いた間葉系幹細胞の培養方法 | |
US20220090008A1 (en) | Colony forming medium and use thereof | |
JP7117020B2 (ja) | 臍帯間葉系幹細胞MSCsの培養法 | |
CN106754668B (zh) | 一种干细胞培养液及注射液 | |
US20150118748A1 (en) | High-concentration stem cell production method | |
KR20070104735A (ko) | 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법 | |
CN106659740A (zh) | 凋亡小体 | |
JP6944165B2 (ja) | 間葉系幹細胞用培地 | |
JP7116501B2 (ja) | 幹細胞材料およびその製造方法 | |
KR20120095022A (ko) | 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 이식편대숙주질환 예방 또는 치료용 세포치료제 조성물 | |
CN112481202B (zh) | 血小板裂解物无血清分离培养脐带间充质干细胞的方法 | |
CN107354127A (zh) | LncRNA‑TUG1在调控PDLSCs成骨分化及组织再生中的作用 | |
CN104758923A (zh) | 一种治疗神经损伤的干细胞制剂及其制备方法 | |
CN109295147B (zh) | 一种促进雨生红球藻中虾青素积累的方法 | |
CN109674818A (zh) | hAMSCs在制备治疗急性移植物抗宿主病药物中的用途 | |
KR102172970B1 (ko) | 감마선 조사 혈청을 이용한 중간엽 줄기세포의 배양방법 | |
KR101624514B1 (ko) | 지방유래 줄기세포 배양방법 | |
JPWO2014185470A1 (ja) | 神経損傷の治療用移植材の製造方法 | |
CN113373108A (zh) | 一种表皮干细胞扩增培养基及其制备方法和应用 | |
KR102132416B1 (ko) | Nadph 산화제의 억제를 통한 기능 강화 중간엽 줄기세포의 용도 | |
CN106754678A (zh) | 一种适用于牙髓干细胞体外培养的培养基及其制备方法 | |
CN112608892A (zh) | 血小板裂解物用于无血清分离和传代培养脐带间充质干细胞的方法 | |
Gulevsky et al. | Stimulating effect of cord blood fraction below 5 kDa and actovegin on cell growth of permanent cell lines | |
KR101590416B1 (ko) | 지방유래 줄기세포 계대배양방법 | |
Da Silva | Photobiomodulated differentiation of adipose-derived mesenchymal stem cells into osteoblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190717 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200923 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210507 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210629 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210726 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6920369 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |